Registered Attendees

Registered Attendees

Print This Page

Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online before the meeting...these abstracts will be available in the Abstract Book at the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

Close Window
Keystone Resort Floorplan

Keystone Resort Floorplan

Print This Page



Close Window

This meeting took place in 2013


Here are the related meetings in 2015:
Integrating Metabolism and Tumor Biology (J1)

For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Tumor Metabolism (X4)


Organizer(s) Matthew G. Vander Heiden and Karen H. Vousden
February 24—March 1, 2013
Keystone Resort • Keystone, Colorado USA
Abstract Deadline: Oct 25, 2012
Late Abstract Deadline: Nov 28, 2012
Scholarship Deadline: Oct 25, 2012
Early Registration Deadline: Dec 19, 2012

Sponsored by AVEO Oncology and Bayer USA Foundation


Summary of Meeting:
Proliferating tumor cells have different metabolic requirements than most normal differentiated cells. All cells consume nutrients to generate ATP and maintain homeostasis, however cell proliferation requires additional nutrient uptake to support macromolecular synthesis needed for cell growth. How metabolic pathways are regulated to balance these needs is not well understood, but mounting evidence suggests that metabolism is actively regulated to support cell growth, and that this regulation is intimately linked with the signal transduction pathways that control cell growth and proliferation. Metabolic changes represent some of the first differences ever noted between tumors and normal tissues. Yet, only recently has it been appreciated that many genetic events associated with cancer result in signal transduction changes to promote metabolism that is conducive to growth. This has accelerated research to understand metabolism in tumors with an eye toward targeting these pathways for improved cancer therapy. Substantial progress in the field has come from laboratories with diverse expertise providing new insights about metabolism and its regulation. However, a deeper understanding of tumor metabolism requires methods to assess metabolite flux and pathway regulation that historically have not been used to study cancer biology. Recent years have seen a remarkable advance in techniques available to interrogate metabolic pathways in vitro and in vivo. This work has been augmented by progress in modeling metabolic networks that facilitate interpretation of complex metabolism data to define key points of regulation. A growing cross talk between these systems biology approaches and traditional cancer biology studies has enabled increasingly sophisticated studies that enhance our understanding of tumor metabolism. Bringing together scientists with expertise in signal transduction, nutrient and oxygen sensing, genetic events affecting metabolism, metabolic flux measurements and network modeling will provide an opportunity to discuss the latest data informing metabolic regulation in tumors. These discussions will impact studies of metabolism in other contexts. Similarly, emerging data related to metabolic regulation in the immune systems can inform studies of tumor metabolism. PI-3 kinase is a critical regulator of metabolism and there have been numerous advances in understanding this signaling pathway; a joint meeting addressing PI-3 Kinase will enrich the dialogue across disciplines to explore how metabolism influences multiple aspects of biology.

View Scholarships/Awards

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


SUNDAY, FEBRUARY 24

15:00—19:30
Arrival and Registration
18:15—19:15
Refreshments
19:15—21:30
Welcome and Keynote Session
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

* Kevan M. Shokat, University of California, San Francisco, USA

* José Baselga, Memorial Sloan-Kettering Cancer Center, USA

* Christian Rommel, Amgen, Inc., USA

Roger L. Williams, Medical Research Council, UK
Tuning Locomotions in the PI3K Pathway


MONDAY, FEBRUARY 25

07:00—08:00
Breakfast
08:00—09:00
Welcome and Keynote Address
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

* Matthew G. Vander Heiden, Massachusetts Institute of Technology, USA

Craig B. Thompson, Memorial Sloan-Kettering Cancer Center, USA
Metabolic Control of Tumor Cell Growth and Survival

09:00—11:00
Metabolic Regulation
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

* Karen H. Vousden, Beatson Institute for Cancer Research, UK

Almut Schulze, University of Würzburg, Germany
The Role of Glucose and Lipid Metabolism in Growth and Survival of Cancer Cells

Linda Z. Penn, Princess Margaret Cancer Centre, Canada
The Mevalonate Pathway, Signaling and Tumor Vulnerability

Daniel S. Peeper, Netherlands Cancer Institute, Netherlands
Short Talk: A Critical Role for the Mitochondrial Gatekeeper Pyruvate Dehydrogenase in Oncogene-Induced Senescence

Jing Chen, Winship Cancer Institute, Emory University, USA
Short Talk: Phosphoglycerate Mutase 1 Coordinates Glycolysis and Biosynthesis to Promote Tumor Growth

08:00—11:15
PI3K/Akt/mTOR Pathway in Cancer (Clinical - Part 1)
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

* José Baselga, Memorial Sloan-Kettering Cancer Center, USA
Breast Cancer

Brett S. Carver, , USA
Targeting the PI3K and AR Pathways in Prostate Cancer: Defining Mechanisms of Response and Resistance

Vito J. Palombella, Infinity Pharmaceuticals, Inc., USA
Development of the Potent PI3K-delta,gamma Inhibitor IPI-145

Khaled Ali, Barts Cancer Institute, UK
Short Talk: Inactivation of p110delta PI 3-Kinase Releases Anti-Tumor Immune Responses

Kyle A. Edgar, Genentech, Inc., USA
Short Talk: Mechanisms of Acquired Resistance to the PI3K Inhibitor, GDC-0941 in Colorectal Cancer Cell Lines

09:40—10:00
Coffee Break
11:00—13:00
Poster Setup
13:00—22:00
Poster Viewing
 
On Own for Lunch and Recreation
14:30—16:30
Workshop 1: Metabolic Regulation and Adaptation
* Matthew G. Vander Heiden, Massachusetts Institute of Technology, USA

Ji Zhang, Memorial Sloan Kettering Cancer Center, USA
Why Cancer Cells Die without Glutamine?

Brandon N. Nicolay, Massachusetts General Hospital Cancer Center, Harvard Medical School, USA
Loss of RBF1 Changes Glutamine Catabolism

Ming Yang, University of Edinburgh, UK
Candidate Roles for Protein Succination in Altered Metabolism and Oncogenesis

Talya L. Dayton, Massachusetts Institute of Technology, USA
Elucidating a Role for Pkm Isoform Expression Specificity in vivo

Darin Salloum, CUNY Hunter College, USA
Human Cancer Cells Harboring Ras Mutations Display Elevated Requirement for Serum Lipids

Wei Liu, Frederick National Laboratory for Cancer Research, National Institutes of Health, USA
Proline Biosynthesis Augments MYC-Induced Aerobic Glycolysis and Cell Growth

16:30—17:00
Coffee Available
17:00—19:00
Nutrient Sensing
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

* Joan S. Brugge, Harvard Medical School, USA

Eileen P. White, Rutgers University, USA
Autophagy Maintains Mitochondrial Function and Tumorigenesis

Matthew G. Vander Heiden, Massachusetts Institute of Technology, USA
Metabolic Pathways Important for Cell Growth

David M. Sabatini, Whitehead Institute for Biomedical Research
Large-Scale Approaches to Study Cancer Metabolism

Issam Ben-Sahra, Harvard University School of Public Health, USA
Short Talk: Growth Signaling Stimulates Nucleotide Synthesis through mTOR

17:00—19:00
PI3K/Akt/mTOR Pathway (Clinical - Part 2)
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

Neal Rosen, Memorial Sloan-Kettering Cancer Center, USA
Interplay Signaling

Kui Lin, Genentech, Inc., USA
Akt

Mark Manfredi, Millennium Pharmaceuticals, USA
The Development of MLN0128, an Investigational mTOR Active Site Inhibitor

Kathryn Balmanno, Babraham Institute, UK
Short Talk: Modelling Acquired Resistance to mTOR Kinase Inhibitors

19:00—20:00
Social Hour with Lite Bites
19:30—22:00
Poster Session 1

TUESDAY, FEBRUARY 26

07:00—08:00
Breakfast
08:00—11:15
Metabolic Adaptation
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

* David M. Sabatini, Whitehead Institute for Biomedical Research

Brian J. Altman, University of Pennsylvania, USA
Regulation of Cell Growth and Metabolism by Myc

Karen H. Vousden, Beatson Institute for Cancer Research, UK
The Role of p53 in Metabolic Adaptation and Survival

Zachary Schug, Beatson Institute for Cancer Research, UK
Targeting Lipid Metabolism in Breast Cancer

Reuben J. Shaw, The Salk Institute, USA
The LKB1 Tumor Suppressor Pathway: Decoding Metabolic Links and Therapeutic Targeting

Costas A. Lyssiotis, Weill Cornell Medical College, USA
Short Talk: Glutamine Metabolism Supports Pancreatic Tumor Growth and Redox Homeostasis

Zhimin Lu, University of Texas MD Anderson Cancer Center, USA
Short Talk: The Warburg Effect and Beyond

08:00—11:15
PI3K/Akt/mTOR Pathway in Cancer (Clinical Translational)
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

* Jeffrey Adam Engelman, Massachusetts General Hospital, USA
Resistance Mechanisms

Sebastian M. B. Nijman, CeMM, Austrian Academy of Sciences, Austria
Gene-Drug Interaction Screens in Cancer

* Lori Friedman, Genentech, Inc., USA
PI3K Inhibitor Combination Therapies

Jonathan M. Backer, Albert Einstein College of Medicine, USA
GPCR–Mediated Activation of p110beta by Gbetagamma Is Required for Cellular Transformation and Invasiveness

Wayne A. Phillips, Peter MacCallum Cancer Centre, Australia
Short Talk: Ubiquitous Expression of a Heterozygous Pik3ca Mutation Results in Increased Body Size, Hypoglycemia and Sudden Death

Mamatha Bhat, Mayo Clinic, USA
Short Talk: Metformin Induces Apoptosis of Hepatocellular Carcinoma Downstream of mTORC1 through eIF4E

09:20—09:40
Coffee Break
11:00—13:00
Poster Setup
13:00—22:00
Poster Viewing
 
On Own for Lunch and Recreation
16:30—17:00
Coffee Available
17:00—19:00
Understanding the Metabolic Network
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

* Ralph J. DeBerardinis, University of Texas Southwestern Medical Center, USA

Tomer Shlomi, Technion, Israel
An Integrated Computational-Experimental Approach for Finding Metabolic Synthetic Lethality in Cancer

Joshua D. Rabinowitz, Princeton University, USA
Revealing Cancer Metabolism with Isotope Tracers

Linda C. Hsieh-Wilson, California Institute of Technology, USA
Linking O-GlcNAc Signaling to Cancer Metabolism and Tumor Growth

Stefan Kempa, Max Delbrück Center for Molecular Medicine, Germany
Short Talk: Quantifying Metabolic Routes in Cancer Cells Using Pulsed Stable Isotope Resolved Metabolomics (pSIRM)

17:00—19:00
PI3K/mTOR Pathway - Signaling Networks (Preclinical)
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

* Kevan M. Shokat, University of California, San Francisco, USA
Chemical Genetic Investigations of Protein and Lipid Kinase Signaling

John Blenis, Weill Cornell Medical College, USA
Convergence and Integration of mTOR and Ras-ERK Signaling in Cancer

David M. Sabatini, Whitehead Institute for Biomedical Research, USA
Regulation of Growth by the mTOR Pathway

Tamara Chessa, Babraham Institute, UK
Short Talk: Dissecting the ClassIA PI3K Signalosome

19:00—20:00
Social Hour with Lite Bites
19:30—22:00
Poster Session 2

WEDNESDAY, FEBRUARY 27

07:00—08:00
Breakfast
08:00—11:00
Influence of the Microenvironment on Metabolism
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

* Sally A. Kornbluth, Duke University Medical Center, USA

Jacques Pouysségur, University of Nice, France
Hypoxia Signaling, pHi Regulation and Tumor Metabolism: Novel Therapeutic Approaches

M. Celeste Simon, HHMI/University of Pennsylvania, USA
Tumor Cell Adaptation to the Microenvironment

Amato J. Giaccia, Stanford University, USA
Oxygen Sensing and Metabolic Control

Brendan D. Manning, Harvard School of Public Health, USA
Tumor Cell Intrinsic Biosynthesis Driven by mTOR Signaling

Russell G. Jones, McGill University, Canada
Short Talk: AMPK Is a Negative Regulator of the Warburg Effect and Suppresses Tumor Growth in vivo

08:00—11:15
PI3K-Related Pathways (Preclinical)
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

* Lewis C. Cantley, Weill Cornell Medical College, USA
PI 3-Kinase, AMPK and Disease

Judith A. Varner, University of California, San Diego, USA
PI3K gamma Control of Innate Immunity in Cancer

Karen M. Cichowski, Brigham and Women's Hospital, Harvard Medical School, USA
Developing Combination Therapies with PI3K/mTOR Pathway Inhibitors

Hong Wu, UCLA/IMED c/o Cyndi Haddad, USA
Cross-Talk between the PI3K and MAPK Pathways Determines Prostate Cancer Metastasis

Kira Gritsman, Dana-Farber Cancer Institute, USA
Short Talk: RAS-Mutated Myeloid Leukemias Are Dependent on the PI3 Kinase Isoform p110alpha

Maurizio Scaltriti, Memorial Sloan-Kettering Cancer Center, USA
Short Talk: p90RSK Mediates Resistance to PI3K-Pathway Inhibitors in Breast Cancer

09:20—09:40
Coffee Break
11:00—13:00
Poster Setup
13:00—22:00
Poster Viewing
 
On Own for Lunch and Recreation
16:30—17:00
Coffee Available
17:00—19:15
Insights from in vivo Experiments
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

* M. Celeste Simon, HHMI/University of Pennsylvania, USA

Tak W. Mak, Campbell Family Institute for Breast Cancer Research at Princess Margaret Hospital, University Health Network, Canada
Tumor Metabolism: Insight from Mouse Models

Yanping Zhang, University of North Carolina at Chapel Hill, USA
The RP-Mdm2-p53 Pathway Links Nutrient Restriction to Lipid Homeostasis

Ralph J. DeBerardinis, University of Texas Southwestern Medical Center, USA
Measuring Metabolism and Metabolites in vivo

Norman Koglin, Piramal Imaging GmbH, Germany
PET Imaging of Glutamate/Cystine Transporter Activity in Cancer Patients

17:00—19:00
PI3K Pathway: Cross-Talk, Feedback, Scaffold (Preclinical)
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

* Christian Rommel, Amgen, Inc., USA

Julian H. Downward, Cancer Research UK, UK
Links between RAS Family GTPases and PI3K Signaling

Peter K. Vogt, The Scripps Research Institute, USA
The PI3K Pathway in Cancer

Pier Paolo Pandolfi, Beth Israel Deaconess Medical Center, Harvard Medical School, USA
Role of Mutant PTEN in Tumorigenesis

John P. O'Bryan, University of Illinois at Chicago, USA
Short Talk: PI3KC2beta: Role in Tumorigenesis and Regulation by Nucleotide-Ras (nf-Ras)

19:15—20:15
Social Hour with Lite Bites
19:30—22:00
Poster Session 3

THURSDAY, FEBRUARY 28

07:00—08:00
Breakfast
08:00—11:00
Targeting Metabolism
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

* Jacques Pouysségur, University of Nice, France

Bing Lim, Genome Institute of Singapore, Singapore
Targeting Glycine Metabolism for Cancer Therapy

Susan E. Critchlow, AstraZeneca, UK
Targeting Lactate Metabolism in Cancer

Sally A. Kornbluth, Duke University Medical Center, USA
Metabolic Control of Caspase 2-Mediated Cell Death

Joan S. Brugge, Harvard Medical School, USA
Use of 3D Culture Models to Understand the Impact of Targeted Therapy on Metabolism

Georgia Hatzivassiliou, Genentech, Inc., USA
Short Talk: Dissecting the Role of Glutaminase in Cancer

Genshi Zhao, Eli Lilly and Company, USA
Short Talk: Pharmacological Inhibition of Nicotinamide Phosphoribosyltransferase (NAMPT), an Enzyme Essential for NAD+ Biosynthesis, in Human Cancer Cells: Metabolic Basis and Potential Clinical Implications

08:00—11:15
PI3K-Related Pathways (Preclinical)
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

* Bart Vanhaesebroeck, University College London, Cancer Institute, UK
PI 3-Kinase Isoforms in Cancer and Metabolism

Davide Ruggero, University of California, San Francisco, USA
Reprogramming Translational Control of mRNA Networks in Cancer and its Therapeutic Implications

Jonathan R. Hart, The Scripps Research Institute, USA
Pulsed SILAC: Enabling the Direct Observation of Changes in Protein Synthesis Caused by mTOR Inhibition

William A. Weiss, University of California, San Francisco, USA
Kinases in Autophagy as Therapeutic Targets in Brain Cancer

Vikki Flemington, AstraZeneca, UK
Short Talk: Phosphatidylinositol-4-Kinase – Potent and Selective Inhibitors of Type III PI 4-Kinases

Emilio Hirsch, Fondazione per la Ricerca Biomedica – ONLUS, Italy
Short Talk: PI3K Class II alpha Controls Primary Cilium Function and Cell Proliferation in Development and Cancer

09:00—09:20
Coffee Break
 
On Own for Lunch and Recreation
15:00—16:30
Workshop 2: Novel Therapeutic Approaches
* Katharine Yen, Agios Pharmaceuticals, USA

Steve Colebrook, Cancer Research UK, UK
A First-in-Man Phase I Trial of AZD3965, a Monocarboxylate Transporter 1 Inhibitor (MCT1), in Patients with Advanced Cancer

Krushna C. Patra, University of Illinois at Chicago, USA
Hexokinase 2 Is Required for Oncogenesis and its Systemic Deletion Is Therapeutic in Mouse Models of Cancer

Alexandra R. Grassian, Novartis Institutes for BioMedical Research, USA
Mutant Isocitrate Dehydrogenase Promotes a Reversible Epithelial-Mesenchymal Transition and Alters Metabolic Flux

Kelly E. Sullivan, Cornell University, USA
Elucidating the Regulation of Mitochondrial Glutaminase in Cancer Progression

David R. Plas, University of Cincinnati, USA
Transition to Fatty Acid Oxidation Mediates Survival of BCR-ABL-Transformed Cells after Inhibition of mTORC1-S6K1

16:30—17:00
Coffee Available
17:00—19:00
Influence of Metabolism on Epigenetic Regulation
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

* Matthew G. Vander Heiden, Massachusetts Institute of Technology, USA

Lewis C. Cantley, Weill Cornell Medical College, USA
Metabolic Control of Histone Methylation

Kathryn E. Wellen, University of Pennsylvania, USA
Use of Metabolic Pathways to Sense Cell State

Katharine Yen, Agios Pharmaceuticals, USA
Mutation Selective IDH Inhibitors Mediate Histone and DNA Methylation Changes

Raul Mostoslavsky, Massachusetts General Hospital, Harvard Medical School, USA
Short Talk: The Histone Deacetylase SIRT6 Suppresses Cancer Metabolism

17:00—19:00
PI3K-Related Pathways (Preclinical)
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

* David A. Fruman, University of California, Irvine, USA
Immune Effects of Anti-Cancer Drugs Targeting PI3K/mTOR

Brendan D. Manning, Harvard School of Public Health, USA
Linking Oncogenic Signaling to Anabolic Metabolism through mTOR

Ramon Parsons, Columbia University, USA
PTEN Signaling

Ralph M. Fritsch, Cancer Research UK London Research Institute, UK
Short Talk: RAS and RHO Family GTPases Directly Regulate Distinct Phosphoinositide 3-Kinase Isoforms

19:00—19:30
Panel Discussion
* Christian Rommel, Amgen, Inc., USA

19:00—20:00
Social Hour with Lite Bites
20:00—23:00
Entertainment

FRIDAY, MARCH 1

 
Departure

*Session Chair †Invited, not yet responded.



Keystone Symposia thanks our Sponsors for generously supporting this meeting:

AVEO Oncology Bayer USA Foundation

We gratefully acknowledge additional support for this conference from:

Cell Signaling Technology, Inc.

We gratefully acknowledge support for this conference from:


Directors' Fund


These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.

Click here to view all of the donors who support the Directors' Fund.



We gratefully acknowledge the generous grant for this conference provided by:


National Institutes of Health

Grant No. 1R13CA174034-01

The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.


We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:



Piramal Imaging GmbH


We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Amanda Deem, Assistant Director of Development, Email: AmandaD@keystonesymposia.org,
Phone:+1 970-262-2668

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676